Medexus Pharmaceuticals Inc. (MEDXF)
| Market Cap | 116.33M +89.1% |
| Revenue (ttm) | 103.30M -2.2% |
| Net Income | -2.37M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 3.620 |
| Previous Close | 3.555 |
| Day's Range | 3.620 - 3.687 |
| 52-Week Range | 1.800 - 3.960 |
| Beta | 1.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAF... [Read more]
Financial Performance
Financial StatementsNews
Medexus Schedules Second Fiscal Quarter 2027 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Nov...
Medexus Pharmaceuticals Transcript: Planet MicroCap Showcase: Toronto 2026
The strategy centers on hematology-oncology, with GRAFAPEX as the near-term growth driver and FY net revenue guidance of $30M–$32M. UM171, portfolio expansion, and real-world data are key supporting priorities.
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareho...
Medexus Pharmaceuticals Transcript: AGM 2026
The meeting covered financial results, elected seven directors, reappointed PwC as auditor, and approved an amendment to the long-term incentive plan. All items passed with shareholder approval, and no questions were raised by participants.
Medexus Pharmaceuticals Slides: Investor presentation
Medexus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Medexus Pharmaceuticals Earnings Call Transcript: Q1 2027
First quarter results showed strong revenue and EBITDA growth, led by GRAFAPEX's record performance and broad adoption, especially in the adult segment. Strategic expansion in Allo-HSCT and stable performance from established products support a positive outlook.
Medexus Pharmaceuticals MD&A: Q1 2027
Medexus Pharmaceuticals filed a regulatory document on August 11, 2026 disclosing important business information.
Medexus Pharmaceuticals Report: Q1 2027
Medexus Pharmaceuticals published a report on August 11, 2026 containing material business information for investors and shareholders.
Medexus Pharmaceuticals Earnings release: Q1 2027
Medexus Pharmaceuticals released its Q1 2027 earnings on August 11, 2026, summarizing the period's financial results.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial tra...
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August ...
Medexus Pharmaceuticals Earnings Call Transcript: Q4 2026
FY2026 saw GRAFAPEX drive growth, offsetting declines from Gleolan and Rupall, with net revenue at $99.3M and adjusted EBITDA at $16.5M. GRAFAPEX is projected to reach $30–$32M in FY2027, while established products are expected to remain stable.
Medexus Pharmaceuticals Earnings release: Q4 2026
Medexus Pharmaceuticals released its Q4 2026 earnings on June 26, 2026, summarizing the period's financial results.
Medexus Pharmaceuticals Report: Q4 2026
Medexus Pharmaceuticals published a report on June 26, 2026 containing material business information for investors and shareholders.
Medexus Pharmaceuticals MD&A: Q4 2026
Medexus Pharmaceuticals filed a regulatory document on June 26, 2026 disclosing important business information.
Medexus Pharmaceuticals Annual report: Q4 2026
Medexus Pharmaceuticals has published its Q4 2026 annual report on June 26, 2026.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Friday, June 26, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX...
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26,...
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel) Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medex...
Medexus Pharmaceuticals Transcript: 16th Annual LD Micro Invitational Conference
Revenue and EBITDA remain stable, with growth now driven by GRAFAPEX, an orphan drug for AML and MDS showing strong early adoption and clinical outcomes. The company is focused on expanding its rare disease portfolio through accretive acquisitions and expects to more than double revenue in the coming years.
Medexus Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
A diversified pharma portfolio is driving steady revenue and EBITDA, with GRAFAPEX poised to double revenue at high margins. Strong hospital uptake, favorable reimbursement, and robust clinical data support U.S. peak sales of $100–$175 million within 3–5 years.
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercializa...
Medexus Pharmaceuticals Slides: Investor presentation
Medexus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.
Medexus Pharmaceuticals Earnings Call Transcript: Q3 2026
GRAFAPEX continues to drive growth, with strong adoption and improving gross margins, despite overall revenue declines due to generic competition and product returns. Cash flow and balance sheet strength have improved, supporting ongoing investments and share repurchases.
Medexus Pharmaceuticals Earnings release: Q3 2026
Medexus Pharmaceuticals released its Q3 2026 earnings on February 12, 2026, summarizing the period's financial results.